| Primary |
| Product Used For Unknown Indication |
17.7% |
| Sarcoma |
11.6% |
| Drug Use For Unknown Indication |
7.0% |
| Germ Cell Cancer |
6.9% |
| Bone Sarcoma |
6.8% |
| Prophylaxis |
6.3% |
| Rhabdomyosarcoma |
6.3% |
| Non-hodgkin's Lymphoma |
5.6% |
| Ewing's Sarcoma |
5.1% |
| Hodgkin's Disease |
5.0% |
| Sarcoma Metastatic |
2.7% |
| Diffuse Large B-cell Lymphoma |
2.6% |
| Nephroblastoma |
2.5% |
| Burkitt's Lymphoma |
2.4% |
| Prophylaxis Of Nausea And Vomiting |
2.3% |
| Head And Neck Cancer |
2.2% |
| Premedication |
1.8% |
| Synovial Sarcoma |
1.8% |
| Lymphoma |
1.7% |
| Neoplasm Malignant |
1.7% |
|
| Encephalopathy |
16.6% |
| Vomiting |
8.0% |
| Thrombocytopenia |
7.6% |
| Neurotoxicity |
6.2% |
| Febrile Neutropenia |
5.5% |
| Death |
5.2% |
| Neutropenic Sepsis |
5.2% |
| Septic Shock |
5.2% |
| Neutropenia |
4.2% |
| Sepsis |
4.2% |
| Tremor |
3.8% |
| Acute Myeloid Leukaemia |
3.5% |
| Mucosal Inflammation |
3.5% |
| Myoclonus |
3.5% |
| Urinary Incontinence |
3.5% |
| Pneumonia |
3.1% |
| Renal Impairment |
3.1% |
| Acute Promyelocytic Leukaemia |
2.8% |
| Renal Tubular Disorder |
2.8% |
| Rickets |
2.8% |
|
| Secondary |
| Burkitt's Lymphoma |
11.6% |
| Diffuse Large B-cell Lymphoma |
10.0% |
| Ewing's Sarcoma |
8.3% |
| Bone Sarcoma |
7.6% |
| Sarcoma |
7.0% |
| Product Used For Unknown Indication |
6.9% |
| Prophylaxis Of Nausea And Vomiting |
5.6% |
| Drug Use For Unknown Indication |
5.1% |
| Hodgkin's Disease |
4.8% |
| Rhabdomyosarcoma |
4.6% |
| Neoplasm Malignant |
4.1% |
| Non-hodgkin's Lymphoma |
3.6% |
| Lymphoma |
3.5% |
| Sarcoma Metastatic |
3.0% |
| Burkitt's Leukaemia |
2.7% |
| Acute Lymphocytic Leukaemia |
2.7% |
| Prophylaxis |
2.7% |
| B-cell Lymphoma |
2.2% |
| Synovial Sarcoma |
2.1% |
| Foetal Exposure During Pregnancy |
1.8% |
|
| Off Label Use |
10.4% |
| Thrombocytopenia |
9.9% |
| Febrile Neutropenia |
9.8% |
| Neutropenia |
7.7% |
| Acute Myeloid Leukaemia |
6.4% |
| Vomiting |
5.8% |
| Mucosal Inflammation |
5.3% |
| Death |
4.8% |
| Encephalopathy |
4.4% |
| Myelodysplastic Syndrome |
4.4% |
| Hearing Impaired |
4.2% |
| Infection |
3.7% |
| Sepsis |
3.7% |
| White Blood Cell Count Decreased |
3.6% |
| Pyrexia |
3.4% |
| Toxicity To Various Agents |
3.4% |
| Premature Baby |
2.6% |
| Pancytopenia |
2.3% |
| Stomatitis |
2.3% |
| Febrile Bone Marrow Aplasia |
2.2% |
|
| Concomitant |
| Drug Use For Unknown Indication |
15.7% |
| Diffuse Large B-cell Lymphoma |
8.3% |
| Product Used For Unknown Indication |
8.2% |
| Prophylaxis |
7.9% |
| Infection Prophylaxis |
7.5% |
| Chemotherapy |
7.0% |
| Non-hodgkin's Lymphoma |
5.4% |
| Ewing's Sarcoma Recurrent |
5.1% |
| Lymphoma |
4.7% |
| B-cell Lymphoma |
3.7% |
| Bone Sarcoma |
3.6% |
| Prophylaxis Against Graft Versus Host Disease |
3.4% |
| Premedication |
2.8% |
| Prophylaxis Of Nausea And Vomiting |
2.7% |
| Neoplasm Malignant |
2.7% |
| Bone Marrow Conditioning Regimen |
2.7% |
| Nuclear Magnetic Resonance Imaging |
2.2% |
| Burkitt's Lymphoma |
2.2% |
| Hodgkin's Disease |
2.0% |
| Pelvic Neoplasm |
2.0% |
|
| Thrombocytopenia |
11.2% |
| Febrile Neutropenia |
10.7% |
| Vomiting |
10.7% |
| Pyrexia |
8.7% |
| Sepsis |
5.8% |
| White Blood Cell Count Decreased |
5.8% |
| White Blood Cell Count Increased |
4.9% |
| Lymphoma |
4.4% |
| Vaginal Infection |
3.9% |
| Asthenia |
3.4% |
| Nephrogenic Systemic Fibrosis |
3.4% |
| Neutropenia |
3.4% |
| Renal Failure Acute |
3.4% |
| Disease Progression |
2.9% |
| Drug Ineffective |
2.9% |
| Enterococcal Infection |
2.9% |
| Nausea |
2.9% |
| Rash |
2.9% |
| Staphylococcal Infection |
2.9% |
| Tetany |
2.9% |
|
| Interacting |
| Ewing's Sarcoma |
24.0% |
| Non-hodgkin's Lymphoma Unspecified Histology Aggressive |
16.6% |
| Non-hodgkin's Lymphoma |
12.4% |
| Premedication |
9.2% |
| Ovarian Cancer Stage Iii |
6.5% |
| Prophylaxis Of Nausea And Vomiting |
6.5% |
| Oral Candidiasis |
3.2% |
| Product Used For Unknown Indication |
3.2% |
| Ovarian Neoplasm |
2.8% |
| Sarcoma Uterus |
2.8% |
| Chemotherapy |
1.8% |
| Ovarian Cancer Metastatic |
1.8% |
| Uterine Leiomyosarcoma |
1.8% |
| Bone Sarcoma |
1.4% |
| Metastasis |
1.4% |
| Antiemetic Supportive Care |
0.9% |
| Antifungal Prophylaxis |
0.9% |
| Nausea |
0.9% |
| Prophylaxis |
0.9% |
| Rhabdomyosarcoma |
0.9% |
|
| Renal Impairment |
13.9% |
| Vomiting |
13.9% |
| Mental Status Changes |
11.1% |
| Encephalopathy |
8.3% |
| Neurotoxicity |
8.3% |
| Paraesthesia |
8.3% |
| Agranulocytosis |
5.6% |
| Drug Interaction |
5.6% |
| Leukopenia |
5.6% |
| Neutropenia |
5.6% |
| Agitation |
2.8% |
| Convulsion |
2.8% |
| Neoplasm Progression |
2.8% |
| Neuropathy Peripheral |
2.8% |
| Toxic Encephalopathy |
2.8% |
|
